Why Scholar Rock Holding Corporation (SRRK) stock moved
Updated Sep 28, 2026
Scholar Rock Holding Corporation (SRRK) shares rose 1.0% to $49.13 at the September 28, 2026 close, a modest gain from the prior close of $48.63. That close is the latest confirmed price for SRRK; a live quote was not available. BestStocks flagged the session as a major change for SRRK. Below, we break down what changed for SRRK, why it matters for investors, how the stock reacted, and the catalysts on the calendar.
What happened
SRRK climbed 1.0% to $49.13
SRRK rose 1.0% in its latest session, moving from $48.63 to $49.13.
ValuationWeak confidence
Rel. volume
—
Calculating
Vs peers
—
No comparable peers
Market cap
—
Earnings in
45d
2026-11-13
Price chart
Aug 31 – Sep 29
E earnings
F filing
A analyst
V/N other
click a marker to highlight
Change events — click to jump to details
What it means for Scholar Rock Holding Corporation investors
For Scholar Rock Holding Corporation investors, the recent signals are mixed, leaving the near-term picture neutral / mixed. On the constructive side: Material positive event; Positive 1.0% session move. Weighing against that: Scholar Rock Holding Corporation (SRRK) moved -5.07% from $50.88 to $48.30 on July 22, 2026; SRRK fell 3.09% intraday to $52.26, continuing pressure from a potential delay in an FDA submission announced Monday that triggered a >13% drop. BestStocks rates the overall signal quality weak (23/100). With earnings roughly 45 days out, the next report is the most likely near-term test of the move.
SRRK price reaction
SRRK last traded at $49.13, up $0.50 (+1.03%) from the previous close of $48.63. Over the past month the stock has ranged between $46.65 and $57.42, and it currently sits about 23% of the way up that band.
The bull and bear case for SRRK stock
Weighing the constructive signals against the risks, here is how the bull and bear case for Scholar Rock Holding Corporation (SRRK) lines up on the latest data.
▲ The bullish case
+Material positive event.
+Positive 1.0% session move.
+SRRK moved +4.99% from its $50.14 open to a $52.64 close on 2026-08-06.
▼ The bearish case
−Scholar Rock Holding Corporation (SRRK) moved -5.07% from $50.88 to $48.30 on July 22, 2026.
−SRRK fell 3.09% intraday to $52.26, continuing pressure from a potential delay in an FDA submission announced Monday that triggered a >13% drop.
−SRRK declined 2.91% to $53.40 intraday, with volume running 47% below historical average for this time of session.
Bull vs bear balanceNeutral / Mixed
BearishNeutralBullish
Weighing both sides, BestStocks' composite read of recent signals is roughly balanced, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.
Scholar Rock shares fell 4.91% to $46.61 as investors engaged in profit-taking following the company's FDA approval of Isembyld (apitegromab) for spinal muscular atrophy on September 11, according to the web catalyst. A Barclays downgrade from Overweight to Equalweight on September 15—citing valuation concerns despite a raised $58 price target—reinforced the selling pressure. Volume was normal at 0.97x expected for this time of session.
Material / Earnings2026-09-14-6.4%
Scholar Rock Holding Corporation (SRRK) moved -8.24% from $56.51 to $51.85 on September 14, 2026, after the FDA approved its spinal muscular atrophy drug ISEMBYLD (apitegromab) ahead of the September 30 PDUFA deadline. The stock had surged over 9% in pre-market trading ($60.45) but reversed sharply in a "sell the news" dynamic as investors locked in profits following the anticipated approval. An unexpected bone fracture warning on the drug's label also contributed to the pullback.
Material / Earnings2026-09-10+1.9%
Scholar Rock Holding Corporation (SRRK) moved +3.07% from $54.01 to $55.67 on 2026-09-10. We checked news, earnings announcements, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found. Volume was near its 5-day average, suggesting the move was not driven by unusual trading activity.
Material / Earnings2026-09-09-4.9%
Scholar Rock Holding Corporation (SRRK) moved -4.61% from $57.26 to $54.62 on 2026-09-09. We checked news, earnings announcements, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found. Volume was 1.6x the 5-day average, indicating modestly elevated trading activity during the decline.
Material / Earnings2026-09-08+3.8%
Scholar Rock Holding Corporation (SRRK) moved +6.16% from $54.09 to $57.42 on September 8, 2026, as investors anticipated the September 30, 2026 FDA decision date for its lead spinal muscular atrophy drug, apitegromab. The BLA was streamlined after removing a troubled manufacturing facility, keeping the review on schedule for the PDUFA action date. The company also recently secured FDA Fast Track and Orphan Drug designations for apitegromab in facioscapulohumeral muscular dystrophy.
Scholar Rock rose 4.52% to $60.88 following positive regulatory updates on its spinal muscular atrophy drug apitegromab. The company announced it removed the Novo Nordisk-owned Catalent Indiana facility from its FDA biologics license application and shifted to an alternate fill-finish facility, while reiterating it expects FDA approval by the September 30 PDUFA date; management added that commercial vials are already produced for immediate launch. Wedbush and JP Morgan recently raised price targets to $63–$64 (Yahoo Finance). Volume trading at 3.01x the historical average at this point in the session.
In-depth SRRK event analyses
Permanent, dated analyses of SRRK's most significant sessions.
Why did Scholar Rock Holding Corporation (SRRK) stock move?
SRRK rose 1.0% to $49.13. No single company-specific catalyst was confirmed during the move window, and it looks technical.
How much did SRRK stock rise?
SRRK gained 1.03% ($0.50) versus the prior close of $48.63, last trading at $49.13.
When is Scholar Rock Holding Corporation's next earnings date?
SRRK's next earnings report is scheduled for 2026-11-13 — about 45 days away.
How BestStocks tracks SRRK
This page is generated automatically by BestStocks' change-detection system after its price and volume cleared SRRK-specific materiality thresholds, triggering an evidence check. It draws on 20 tracked change events for SRRK, cross-checked against the data sources listed below. A live intraday quote was not available, so price and volume figures are the confirmed end-of-day close from September 28, 2026 — not the current price — and the percentage move is that session's. They refresh once live quotes resume. For companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.
Data sources
FMP real-time & historical price dataSEC EDGAR filingsEarnings calendar (FMP)
Educational research tool — not personalized investment advice. Data may be delayed.
